MacroGenics (MGNX) stock

Cancer therapeutics , market cap $141M

Antibody-based therapeutics for cancer

Worth $141M

Pre-market

$2.33

0.00%

Close $2.33 +4.96%

As of 8:53 AM ET pre-market, delayed 15+ min · Live for Pro members

Why MGNX fell on Oct 23

Down 38% on Oct 23, and still 36% under its Oct 22 close.

MacroGenics fell 38% that day while pharma stocks fell a median 0.9%: it trailed its group by 37 points.

Sources: Price history, Oct 23, 2026

−2Long-term trend below a falling 200-day average, down over two years

Tell me next time MGNX moves

Free account, no card. An optional alert when MGNX moves or its score changes.

Or see it live, free until tomorrow morning. No account.

1 more reason, free with an account →2 more reasons why MGNX fell on Oct 23, from its filings, with how the business stands, the timeline, and its peers, for Pro members.

Why MGNX still beats the market over a year

Up 71% over the year to Nov 6 while the S&P 500 rose 11%; down 38% on Oct 23.

5 reasons, from its filings, with the timeline, for Pro members.

Quality Score

-2

Poor

In its industry

#67of 90

Pharma

Checks firing

2of 14

Trending down

From 52-week high

-54.1%

under its best in a year

MGNX's Quality Score rose 1 point on Fri, Nov 6, to -2. Trading was quieter than usual (2 chart checks started).

Follow MGNX's trial news. Pro members can get an alert when MacroGenics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MGNX files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextLate 2026“…(ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026”Trial data · SEC filing · Aug 13

Cash$114M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30 · the company says “through 2028”

Key facts on MGNX

Key facts on MGNX
Since its Nov 2021 high	Down 90% while sales grew 117%
Latest filing	8-K, Nov 3 Reported a change of officers or directors

1 more reason behind MGNX's -2, free with an account →3 more reasons behind MGNX's -2, for Pro members.

MGNX in the news

ReportExpected to report Thursday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 4 of its last 4 reports, +19.6% on average. Past reports ›

What's next

Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$114M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30 · the company says “through 2028”

MGNX catalysts

Coming up

After its last 4 reports it closed +19.6% on average, higher 4 of 4 times.

4 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for MGNX, and how long its cash lasts

Next step the company has named

Late 2026“MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026”Trial data · SEC filing · Aug 13

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: MGC028 · Advanced Solid Tumors · Phase 1
Its trial: MGC028 in Participants With Advanced Solid TumorsPhase 1 · Recruiting · 124 people · main data estimated Nov 2026 · NCT06723236

4 more trials, 1 with data due this year, 2 more milestones and 36 filings, for Pro members.

Cash runway Jun 30 balance sheet

$114M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “through 2028” (8-K, Aug 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

An officer, Jeffrey Stuart Peters, sold 31,105 shares on Aug 19, under a planned sale.

From Form 4: open-market buys and sales only.

Get an alert when Scott Koenig buys or sells

For Pro members: every trade, and Scott Koenig’s 7 filings and quotes.

Get an alert when MGNX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How MGNX ranks in Pharma

MGNX is #67 of 90 by Quality Score.

How MGNX ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	LQDALiquidia		Open for its score
	MANEVeradermics		Open for its score
	MNKDMannkind		Open for its score
	MRKMerck		Open for its score
67	MGNXMacroGenics	2/14	-2

When does MGNX report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 3 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MGNX reported on Aug 13, 2026

The quarter

The figures are not read from the release yet.

“The increase was primarily due to achievement of the $24.5 million regulatory milestone from Sanofi related to U.S. approval of TZIELD.”

The filing on EDGAR

Where the sales came from

MGNX's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Through 2028
Cash runway	through 2028

Figures as filed (SEC filing, Aug 13)

The numbers

Market value: $141M; today
Sales: $168M; up 11.7% on the year
Free cash flow: -$65.5M; last 12 months

Sales grew 7.3% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 3.8% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MGNX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+45.3%+20.6%+3.4%

Mar 9May 13Aug 13

Reported	When	Gap	Reaction	5 days
Aug 13, 2026After close	After close	-5.8%	+3.4%	-0.3%
May 13, 2026After close	After close	+4.6%	+20.6%	+29.3%
Mar 9, 2026After close	After close	+2.5%	+45.3%	+31.4%

MGNX closed higher after 4 of its last 4 reports.

All 4 reports, and MGNX's Quality Score going into each

Everyone reporting earnings this week

MGNX sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $150M in 2025. It lost money in each of the eight years.

MGNX has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on MGNX, and all 14 on every stock.Get in free →

MGNX RSI on Nov 6: 33.2, below its 50-day and 200-day averages

Not scored

RSI 33.2, MACD below signal, below both averages. Not scored.13 readings

The deep dive on MGNX

What it does and how it makes money3 findingsRevenue From Collaborative Agreements made up 58% of its revenue in fiscal 2025 ($87.2M of $150M), against 80% in fiscal 2024; contract manufacturing 35% and RevenueFromRoyalityAgreementsMember 6%.SEC filing · Mar 9, 2026
Where it stands2 findingsFor Pro members2 findings on where MGNX stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"MacroGenics, Inc. (Case No. 24-cv-02184), was filed in the U.S. District Court for the District of Maryland against the Company and Scott Koenig …" (10-K for fiscal 2025)SEC filing · Mar 9, 2026A new heading in its "Risk Factors" this year: "Our manufacturing facility is not currently being primarily utilized for the production of our own product candidates, and we may not be able to efficiently and effectively offset the costs of maintaining the facility through contract manufacturing services …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 9, 2026, against the one of Mar 20, 2025Sanofi S.A. made up 33% of its revenue in fiscal 2025; Incyte Corporation made up 32%, down from 76% in fiscal 2024.SEC filing · Mar 9, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades MGNX, for Pro members

8 more findings on MGNX, each with its source, for Pro members.

MGNX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Eric Blasius RisserPresident and CEO · no trades on file
James KarrelsSVP and CFO · no trades on file
Jeffrey Stuart PetersSenior VP, GC, and Secretary · 1 trade
Beth Ann SmithVP, Controller & Treasurer · no trades on file
Ezio BonviniSr VP, Research & CSO · no trades on file
Thomas SpitznagelSr VP, Technical Ops · no trades on file
David C. StumpDirector · no trades on file
Edward HurwitzDirector · no trades on file

8 more officers and directors file at MGNX.

See insider trades by person

Which ETFs hold MGNX?

In ETFs: MGNX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About MacroGenics

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

293 employeesRockville, MDmacrogenics.com

What MacroGenics says it competes with

“We also face intensifying competition worldwide, including in China where research and development capabilities have expanded and accelerated significantly.”

From its annual report, SEC filing · Mar 9, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on MGNX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn MGNX's score around: 8 things
3 more filings explained, a plain line each
3 more things pulling MGNX's score down

See MGNX's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: MGNX's Quality Score is -2 (Poor), #67 of 90 in Pharma.

What does MGNX's Quality Score say?

MGNX scores -2 today, which Breakaway calls Poor. It is #67 of 90 in Pharma by Quality Score, with 2 of 14 chart checks firing. Down 38% on Oct 23, and still 36% under its Oct 22 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MGNX's Quality Score?

MGNX scores -2 today, which Breakaway calls Poor (below zero). That is #67 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MGNX's -2.

When does MGNX report earnings?

Expected to report Thu Nov 12, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. MGNX closed higher after 4 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.